Betaksolol

Betaksolol
(IUPAC) ime
	(RS)-14-[2-(ciklopropilmetoksi)etil]-; fenoksi3-(izopropilamino)propan-2-ol
Klinički podaci
Robne marke	Kerlon
AHFS/Drugs.com	Monografija
MedlinePlus	a609023
Identifikatori
CAS broj	63659-18-7
ATC kod	C07AB05 S01ED02
PubChem	2369
DrugBank	DB00195
ChemSpider	2279
UNII	O0ZR1R6RZ2
KEGG	D07526
ChEBI	CHEBI:3082
ChEMBL	CHEMBL423
Hemijski podaci
Formula	C18H29NO3
Mol. masa	307,428 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3 ; Key: NWIUTZDMDHAVTP-UHFFFAOYSA-N
Farmakokinetički podaci
Bioraspoloživost	89%
Metabolizam	Hepatički
Poluvreme eliminacije	14–22 sata
Izlučivanje	Renalno (20%)
Farmakoinformacioni podaci
Trudnoća	C(AU) C(US)
Pravni status	℞ Prescription only
Način primene	oralno, okularno

Betaksolol (Betoptik, Betoptik S, Lokren, Kerlon) je selektivni blokator beta₁ receptora koji se koristi u tretmanu hipertenzije i glaukoma.^[6]^[7] Pošto je selektivan za beta₁ receptore, on tipično ima manje nuspojava od neselektivnih beta blokatora. Na primer on ne uzrokuje bronhospazme (posredovane beta₂ receptorima) poput timolola. Betaksolol takođe pokazuje veći afinitet za beta₁ receptore od metoprolola. Osim njegovog dejstva na srce, betaksolol redukuje pritisak unutar oka (intraokularni pritisak). To dejstvo je verovatno posledica umanjenog formiranja tečnosti unutar oka. Precizni mehanizam nije poznat. Umanjenjem intraokularnog pritiska se smanjuje rizik od oštećenja optičkih nerva i gubitak vida kod pacijenata sa povišenim intraokularnim pritiskom usled glaukoma.

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
↑ Pdr Staff (2009). PDR: Physicians Desk Reference 2010 (Physicians' Desk Reference (Pdr)). Rozelle, N.S.W: Thomson Reuters. ISBN 1-56363-748-0.

Povezano

Levobetaksolol

Spoljašnje veze

	Portal Medicina
	Portal Hemija

Kerlone prescribing information

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[Goodman_Gilman-6] Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.

[PDR-7] Pdr Staff (2009). PDR: Physicians Desk Reference 2010 (Physicians' Desk Reference (Pdr)). Rozelle, N.S.W: Thomson Reuters. ISBN 1-56363-748-0.

[1]

[2]

[3]

[4]

[5]

[6]

[7]